publication . Article . 2013

Diabetes tipo 2 y obesidad leve: tratamiento quirúrgico

Enrique Lanzaren S;
Open Access Spanish
  • Published: 01 Feb 2013
  • Publisher: Sociedad de Cirujanos de Chile
Abstract
Introducción: En la actualidad la diabetes mellitus tipo 2 (DM2) y la obesidad representan un serio problema de salud, comportándose como enfermedades epidémicas. Existe un gran interés en explorar distintas opciones de tratamiento de la DM2 en pacientes que no tienen obesidad mórbida. Objetivo: Reportar los parámetros de control glicémico en pacientes con DM2 y obesidad leve sometidos a bypass gástrico (BPG) a 3 años de seguimiento. Metodología: Estudio clínico prospectivo que incluye pacientes con DM2 con un IMC entre 30 y 35 kg/m² que se sometieron a bypass gástrico laparoscópico desde julio de 2008 hasta octubre de 2010 como tratamiento de su DM2. Resultados...
Subjects
free text keywords: Tipe 2 diabetes, surgery, mild obesity, Diabetes tipo 2, cirugía, obesidad leve, Gynecology, medicine.medical_specialty, medicine, business.industry, business, Diabetes mellitus, medicine.disease
Related Organizations
35 references, page 1 of 3

1. Zimmet P. The burden of type 2 diabetes: are we doing enough? Diabetes Metab. 2003;29:9-18.

2. Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53. [OpenAIRE]

3. Encuesta Nacional de Salud 2009-2010. Ministerio de Salud. Gobierno de Chile.

4. Donnelly R, Emslie Smith A, Gardner I, Morris A. Complications of Diabetes. BMJ 2000;320:1062-6.

5. Geiss L, Herman W, Smith P. Mortality in non insulindependent diabetes.”Diabetes in America” 2nd edition. National diabetes data group. National Health Institutes. National Institute of Diabetes and Digestive and Kidney Diseases NIH Publication. 1995;95:1468.

6. Haffner S, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from Coronary Heart Disease in subjects with Type 2 Diabetes and in nondiabetic subjects with or without prior myocardial infarction. N Eng J Med. 1998;339:229-34.

7. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPD 34). Lancet 1998;352:854-65.

8. Heine R, Diamant M, Mbanya J-C, Nathan D. Management of Hyperglycemia in Type 2 Diabetes: The End of Recurrent Failure? BMJ 2006;333:1200-4.

9. Dailey G, Kim M, Lian J. Patient Compliance and Persistence with Anti-Hyperglycemic Therapy: Evaluation of a Population of Type 2 Diabetic Patients. J Int Med Res. 2002;30:71-9.

10. Kahn S, Haffner S, Heise M, Herman W, Holman R, Jones N, et al, for the ADOPT Study Group. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. N Engl J Med. 2006;355:2427-43.

11. Dormandy J, Charbonnel B, Eckland D, Erdmann E, Massi-Benedetti M, Moules I, et al., On behalf of the PROactive Investigators. Secondary Prevention on Macrovascular Events in Patients with Type 2 Diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A Randomised Controlled Trial. Lancet 2005;366:1279-89.

12. Lago R, Singh P, Nesto R. Congestive Heart Failure and Cardiovascular Death in Patients with Prediabetes and Type 2 Diabetes Given Thiazolidinediones: A Meta-Analysis of Randomised Clinical Trials. Lancet 2007;370:1129-36.

13. Parks M, Rosenbraugh C. Weighing risks and benefits of liraglutide-the FDA's review of a new anidiabetic therapy. N Eng J Med. 2010;362:774-7.

14. Rubino F, Gagner M. Potential of Surgery for Curing Type 2 Diabetes Mellitus. Ann Surg. 236:554-9.

15. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724-37.

35 references, page 1 of 3
Abstract
Introducción: En la actualidad la diabetes mellitus tipo 2 (DM2) y la obesidad representan un serio problema de salud, comportándose como enfermedades epidémicas. Existe un gran interés en explorar distintas opciones de tratamiento de la DM2 en pacientes que no tienen obesidad mórbida. Objetivo: Reportar los parámetros de control glicémico en pacientes con DM2 y obesidad leve sometidos a bypass gástrico (BPG) a 3 años de seguimiento. Metodología: Estudio clínico prospectivo que incluye pacientes con DM2 con un IMC entre 30 y 35 kg/m² que se sometieron a bypass gástrico laparoscópico desde julio de 2008 hasta octubre de 2010 como tratamiento de su DM2. Resultados...
Subjects
free text keywords: Tipe 2 diabetes, surgery, mild obesity, Diabetes tipo 2, cirugía, obesidad leve, Gynecology, medicine.medical_specialty, medicine, business.industry, business, Diabetes mellitus, medicine.disease
Related Organizations
35 references, page 1 of 3

1. Zimmet P. The burden of type 2 diabetes: are we doing enough? Diabetes Metab. 2003;29:9-18.

2. Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53. [OpenAIRE]

3. Encuesta Nacional de Salud 2009-2010. Ministerio de Salud. Gobierno de Chile.

4. Donnelly R, Emslie Smith A, Gardner I, Morris A. Complications of Diabetes. BMJ 2000;320:1062-6.

5. Geiss L, Herman W, Smith P. Mortality in non insulindependent diabetes.”Diabetes in America” 2nd edition. National diabetes data group. National Health Institutes. National Institute of Diabetes and Digestive and Kidney Diseases NIH Publication. 1995;95:1468.

6. Haffner S, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from Coronary Heart Disease in subjects with Type 2 Diabetes and in nondiabetic subjects with or without prior myocardial infarction. N Eng J Med. 1998;339:229-34.

7. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPD 34). Lancet 1998;352:854-65.

8. Heine R, Diamant M, Mbanya J-C, Nathan D. Management of Hyperglycemia in Type 2 Diabetes: The End of Recurrent Failure? BMJ 2006;333:1200-4.

9. Dailey G, Kim M, Lian J. Patient Compliance and Persistence with Anti-Hyperglycemic Therapy: Evaluation of a Population of Type 2 Diabetic Patients. J Int Med Res. 2002;30:71-9.

10. Kahn S, Haffner S, Heise M, Herman W, Holman R, Jones N, et al, for the ADOPT Study Group. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. N Engl J Med. 2006;355:2427-43.

11. Dormandy J, Charbonnel B, Eckland D, Erdmann E, Massi-Benedetti M, Moules I, et al., On behalf of the PROactive Investigators. Secondary Prevention on Macrovascular Events in Patients with Type 2 Diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A Randomised Controlled Trial. Lancet 2005;366:1279-89.

12. Lago R, Singh P, Nesto R. Congestive Heart Failure and Cardiovascular Death in Patients with Prediabetes and Type 2 Diabetes Given Thiazolidinediones: A Meta-Analysis of Randomised Clinical Trials. Lancet 2007;370:1129-36.

13. Parks M, Rosenbraugh C. Weighing risks and benefits of liraglutide-the FDA's review of a new anidiabetic therapy. N Eng J Med. 2010;362:774-7.

14. Rubino F, Gagner M. Potential of Surgery for Curing Type 2 Diabetes Mellitus. Ann Surg. 236:554-9.

15. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724-37.

35 references, page 1 of 3
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue